open access

Vol 15, No 2 (2018)
Review paper
Published online: 2018-06-27
Get Citation

Cariprazine — antipsychotic with partial dopaminergic agonist propeties

Przemysław Bieńkowski
Psychiatria 2018;15(2):77-81.

open access

Vol 15, No 2 (2018)
Prace poglądowe - nadesłane
Published online: 2018-06-27

Abstract

The paper presents the pharmacological profile of cariprazine, a new antipsychotic drug. Cariprazine is a partial agonist of
dopamine receptors. It is used at doses of 1.5–6.0 mg/day in the pharmacological treatment of schizophrenia. Cariprazine like
other partial dopamine receptor agonists, and in contrast to classical antagonists — does not block dopamine transmission in
a zero-one manner. The signal transmitted by dopamine cells in the limbic system is weakened by cariprazine, but not completely
blocked, and this action of cariprazine is sufficient to obtain an antipsychotic effect. Lack of a full antagonistic effect
on D2 and D3 receptors may limit adverse subjective reactions to the medication, including the severity of symptomatology of
depression and secondary negative symptoms.

Abstract

The paper presents the pharmacological profile of cariprazine, a new antipsychotic drug. Cariprazine is a partial agonist of
dopamine receptors. It is used at doses of 1.5–6.0 mg/day in the pharmacological treatment of schizophrenia. Cariprazine like
other partial dopamine receptor agonists, and in contrast to classical antagonists — does not block dopamine transmission in
a zero-one manner. The signal transmitted by dopamine cells in the limbic system is weakened by cariprazine, but not completely
blocked, and this action of cariprazine is sufficient to obtain an antipsychotic effect. Lack of a full antagonistic effect
on D2 and D3 receptors may limit adverse subjective reactions to the medication, including the severity of symptomatology of
depression and secondary negative symptoms.

Get Citation

Keywords

cariprazine, schizophrenia, pharmacologic profile, dopamine, partial agonist

About this article
Title

Cariprazine — antipsychotic with partial dopaminergic agonist propeties

Journal

Psychiatria (Psychiatry)

Issue

Vol 15, No 2 (2018)

Article type

Review paper

Pages

77-81

Published online

2018-06-27

Bibliographic record

Psychiatria 2018;15(2):77-81.

Keywords

cariprazine
schizophrenia
pharmacologic profile
dopamine
partial agonist

Authors

Przemysław Bieńkowski

References (20)
  1. Schatzberg A, Nemeroff C. The American Psychiatric Association Publishing Textbook of Psychopharmacology. 2017.
  2. Stahl SM. Modes and nodes explain the mechanism of action of vortioxetine, a multimodal agent (MMA): enhancing serotonin release by combining serotonin (5HT) transporter inhibition with actions at 5HT receptors (5HT1A, 5HT1B, 5HT1D, 5HT7 receptors). CNS Spectr. 2015; 20(2): 93–97.
  3. Caraci F, Leggio GM, Salomone S, et al. New drugs in psychiatry: focus on new pharmacological targets. F1000Res. 2017; 6: 397.
  4. Frankel JS, Schwartz TL. Brexpiprazole and cariprazine: distinguishing two new atypical antipsychotics from the original dopamine stabilizer aripiprazole. Ther Adv Psychopharmacol. 2017; 7(1): 29–41.
  5. Ye Na, Song Z, Zhang Ao. Dual ligands targeting dopamine D2 and serotonin 5-HT1A receptors as new antipsychotical or anti-Parkinsonian agents. Curr Med Chem. 2014; 21(4): 437–457.
  6. McCreary AC, Newman-Tancredi A. Serotonin 5-HT1A Receptors and Antipsychotics - An Update in Light of New Concepts and Drugs. Curr Pharm Des. 2015; 21(26): 3725–3731.
  7. Muneer A. Pharmacotherapy of Acute Bipolar Depression in Adults: An Evidence Based Approach. Korean J Fam Med. 2016; 37(3): 137–148.
  8. Krause M, Zhu Y, Huhn M, et al. How well do patients with a first episode of schizophrenia respond to antipsychotics: A systematic review and meta-analysis. Eur Neuropsychopharmacol. 2017; 27(9): 835–844.
  9. Misiak B, Bieńkowski P, Samochowiec J. Kariprazyna – nowy lek przeciwpsychotyczny i jego miejsce w leczeniu schizofrenii. Psychiatria Pol. 2017; 83: 1–14.
  10. Citrome L, Citrome L. Cariprazine in schizophrenia: clinical efficacy, tolerability, and place in therapy. Adv Ther. 2013; 30(2): 114–126.
  11. Citrome L. Cariprazine for the Treatment of Schizophrenia: A Review of this Dopamine D3-Preferring D3/D2 Receptor Partial Agonist. Clin Schizophr Relat Psychoses. 2016; 10(2): 109–119.
  12. Leggio GM, Bucolo C, Platania CB, et al. Current drug treatments targeting dopamine D3 receptor. Pharmacol Ther. 2016; 165: 164–177.
  13. Stahl SM. Mechanism of action of cariprazine. CNS Spectr. 2016; 21(2): 123–127.
  14. Corponi F, Serretti A, Montgomery S, et al. Cariprazine specificity profile in the treatment of acute schizophrenia: a meta-analysis and meta-regression of randomized-controlled trials. Int Clin Psychopharmacol. 2017; 32(6): 309–318.
  15. Garnock-Jones KP. Cariprazine: A Review in Schizophrenia. CNS Drugs. 2017; 31(6): 513–525.
  16. Scarff JR. Cariprazine for Schizophrenia and Bipolar Disorder. Innov Clin Neurosci. 2016; 13(9-10): 49–52.
  17. Mauri MC, Paletta S, Maffini M, et al. Clinical pharmacology of atypical antipsychotics: an update. EXCLI J. 2014; 13: 1163–1191.
  18. Lao KSJ, He Y, Wong ICK, et al. Tolerability and Safety Profile of Cariprazine in Treating Psychotic Disorders, Bipolar Disorder and Major Depressive Disorder: A Systematic Review with Meta-Analysis of Randomized Controlled Trials. CNS Drugs. 2016; 30(11): 1043–1054.
  19. Solmi M, Murru A, Pacchiarotti I, et al. Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review. Ther Clin Risk Manag. 2017; 13: 757–777.
  20. Fang F, Sun H, Wang Z, et al. Antipsychotic Drug-Induced Somnolence: Incidence, Mechanisms, and Management. CNS Drugs. 2016; 30(9): 845–867.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest Via Medica sp. z o.o. sp. komandytowa, ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl